retatrutide trial results Breaking: New data just released. TRIUMPH-1 study on the triple agonist. Eli Lilly's clinical trial on Retatrutide (triple agonist compound). 80 weeks. Phase 3 data. The results: At 12mg Retatrutide Results: 28.3% Weight Loss

The company also reported a 14.2% decrease on its end of period subscribers for the quarter, and a net loss of $72.6 million

How much protein do I need on a GLP-1 medication

Disability-adjusted life years due to stroke have been constantly increasing since 1990 and were up 32.4% in 2019 (Roth et al., 2020)

The bigger, long-term question is: if patients become significantly healthier through these medications, will they still need treatments for heart disease, high cholesterol, and related conditions

doi: 10.1186/1744-8069-8-16 66 KimN

Mechanisms underlying the blood pressure lowering effects of dapagliflozin, exenatide, and their combination in people with type 2 diabetes: a secondary analysis of a randomized trial